Press Releases

Claritas Pharmaceuticals, Inc.  announced that it has entered into an agreement with CMAX Clinical Research Pty Ltd (“CMAX”) to conduct a randomized, placebo-controlled, single-blind, single ascending dose Phase 1 clinical study to evaluate the pharmacokinetics and safety profile of the Company’s novel, liquid, nitric oxide-releasing drug, R-107. R-107 is a Nitric Oxide-Releasing Compound R-107 is a liquid, nitric oxide-releasing compound with issued

Enclara Pharmacia, the market leader in comprehensive pharmacy management services for the hospice community, announced the launch of a new medication interface with NDoc, an electronic medical records (EMR) and overall software solution created by Thornberry Ltd specifically for the unique needs of the home health and hospice sectors. “This integration complements our existing demographic interface with NDoc to allow our mutual clients to seamlessly route admissions, eligibil

MedPharm Holdings, a leading cannabis researcher and manufacturer, announces that they have been granted a patent today for a unique invention: a water-soluble powdered cannabinoid and/or terpene extract. The inventor of MedPharm’s powdered cannabinoid formulation, Scott Karolchyk, MS, RPh, has been developing various health and pharmaceutical formulations for over 18 years, and has been granted over a dozen patents. The U.S. patent number 10,980,743 is one of the co

Abzena is a Global Partner Research Organization (PRO) specializing in the integrated development and manufacture of complex biologics and bioconjugates has announced that the location of its new GMP manufacturing facility will be Sanford, North Carolina.   The significant expansion of Abzena’s capacity is driven by an increase in customer demand for commercial scale 2000L single use bioreactors across a wide range of therapeutic areas.  Sanford will be Abzena’s 6th

MannKind Corporation and United Therapeutics reached a milestone in the development of Tyvaso DPI™ as United Therapeutics submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA). “The NDA submitted today by United Therapeutics builds upon a drug master file previously submitted by MannKind,” said Michael Castagna, CEO of MannKind Corporation. “We are excited to see the second compound formulated with our technology complete a rig

Terumo Blood and Cell Technologies and CSL Plasma announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial of the investigational plasmapheresis device began earlier this month, and introduction of the new platform is subject to U.S. Food and Drug Administration device clearance, at which time the parties will provide further comment. Plasma is a key ingredient for therapies crucial to treating patients around the w

Lyndra Therapeutics, a clinical-stage biotechnology company working to make daily pills a thing of the past, announced results from its Phase 2 study of LYN-005, the Company’s oral, ultra-long-acting, extended-release (ER) risperidone capsule, in development for the weekly treatment of schizophrenia. These data, from the Company’s first repeat dose Phase 2 study in patients, demonstrate that LYN-005 provided sustained therapeutic levels of risperidone over the one-week dosing inte

The U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. Based on its ongoing analysis of emerging scientific data, specifically the sustained increase of SARS-CoV-2 viral variants that are resistant to bamlanivimab alone resulting in the increased risk for treatmen

ProBioGen announced today that Nouscom has activated a commercial product license to ProBioGen's innovative, cell-based vaccine platform AGE1.CR.pIX. ProBioGen's AGE1.CR.pIX cell line was designed for large scale industrial production of various vaccines and viral vectors. The cell line was developed at ProBioGen from primary duck cells, is adapted to suspension-growth and comes with a specifically designed, chemically-defined medium and full documentation. Elisa S

Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced that Merck, known as MSD outside the United States and Canada, will make to Sutro a $15 million milestone payment for the initiation of an IND enabling toxicology study for the first program in its collaboration to develop novel cytokine derivative ther